Shen, Haifa
Stemirna Therapeutics,
China
2025 Rank: 175010
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 5371 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 175010 | 198353 |
| Total Cites | 1872 | 1927 |
| H-index | 14 | 15 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 28 | 28 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 231 | 241 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1775 | 1813 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.06 |
| Self-Citation Percentage |
2.85%
|
|
Shen, Haifa
Stemirna Therapeutics,
China
2024 Rank: 178134
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 5875 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 178134 | 205382 |
| Total Cites | 1742 | 1801 |
| H-index | 13 | 13 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 22 | 22 |
| Number of Single+First+Last Authored Papers | 53 | 53 |
| Total Cites to Single+First+Last Authored Papers | 230 | 244 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1674 | 1719 |
| Ratio of Total Citations to Distinct Citing Papers | 1.04 | 1.05 |
| Self-Citation Percentage |
3.28%
|
|
Shen, Haifa
StemiRNA Therapeutics,
China
2023 Rank: 158154
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 5634 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 158154 | 172971 |
| Total Cites | 1817 | 1901 |
| H-index | 16 | 16 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 19 | 23 |
| Number of Single+First+Last Authored Papers | 52 | 52 |
| Total Cites to Single+First+Last Authored Papers | 263 | 286 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1717 | 1770 |
| Ratio of Total Citations to Distinct Citing Papers | 1.06 | 1.07 |
| Self-Citation Percentage |
4.42%
|
|
Shen, Haifa
Houston Methodist,
United States
2022 Rank: 150543
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 5676 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 150543 | 152677 |
| Total Cites | 1890 | 2023 |
| H-index | 15 | 16 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 24 | 28 |
| Number of Single+First+Last Authored Papers | 50 | 50 |
| Total Cites to Single+First+Last Authored Papers | 242 | 275 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1821 | 1902 |
| Ratio of Total Citations to Distinct Citing Papers | 1.04 | 1.06 |
| Self-Citation Percentage |
6.57%
|
|
Shen, Haifa
Houston Methodist,
United States
2021 Rank: 143317
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 5142 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 143317 | 139481 |
| Total Cites | 2900 | 3134 |
| H-index | 18 | 20 |
| Hm-index | 5 | 6 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 43 | 50 |
| Number of Single+First+Last Authored Papers | 44 | 44 |
| Total Cites to Single+First+Last Authored Papers | 369 | 432 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2772 | 2907 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.08 |
| Self-Citation Percentage |
7.47%
|
|
Shen, Haifa
Methodist Hospital Houston,
United States
2020 Rank: 125320
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 4348 out of 230678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 125320 | 116253 |
| Total Cites | 2139 | 2343 |
| H-index | 15 | 17 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 45 | 56 |
| Number of Single+First+Last Authored Papers | 42 | 42 |
| Total Cites to Single+First+Last Authored Papers | 272 | 335 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2040 | 2132 |
| Ratio of Total Citations to Distinct Citing Papers | 1.05 | 1.10 |
| Self-Citation Percentage |
8.71%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.